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Aims/hypothesis Impaired angiogenesis induced by vascular endothelial growth factor (VEGF) 
resistance is a hallmark of vascular complication in type 2 diabetes; however, its molecular mechanism 
is not fully understood. We have previously identified selenoprotein P (SeP, encoded by SEPP1 gene in 
humans) as a liver-derived secretory protein that induces insulin resistance. Levels of serum SeP and 
hepatic expression of SEPP1 are elevated in type 2 diabetes. Here, we investigated the effects of SeP 
on VEGF signaling and angiogenesis. 
Methods We assessed the action of glucose on Sepp1 expression in cultured hepatocytes. We examined 
actions of SeP on VEGF signaling and VEGF-induced angiogenesis in Human vascular endothelial 
cells (HUVECs). We assessed wound healing in mice with hepatic SeP over-expression or SeP deletion. 
The blood flow recovery after ischaemia was also examined by using hindlimb ischaemia model with 
Sepp1 heterozygous knockout mice. 
Results Treatment with glucose increased gene expression and transcriptional activity for Sepp1 in 
H4IIEC hepatocytes. Physiological concentrations of SeP inhibited VEGF-stimulated cell 
proliferation, tubule formation and migration in HUVECs. SeP suppressed VEGF-induced reactive 
oxygen species (ROS) generation and phosphorylation of VEGFR2 and ERK 1/2 in HUVECs. Wound 
closure was impaired in the mice overexpressing Sepp1, whereas it was improved in SeP-/- mice. SeP+/- 
mice showed an increase of the blood flow recovery and vascular endothelial cells after hindlimb 
ischaemia. 
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Conclusions/interpretation The hepatokine SeP may be a novel therapeutic target for impaired 
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Abbreviation 
HUVECs    Human vascular endothelial cells 
MAPK       Mitogen-activated protein kinase 
ROS           reactive oxygen species 
SeP           selenoprotein P 
VEGF        vascular endothelial growth factor 
 
Introduction 
Type 2 diabetes is a chronic hyperglycemic condition that causes various vascular complications, 
including damage to small blood vessels resulting in retinopathy, nephropathy, and neuropathy, and 
damage to large blood vessels resulting in cardiovascular diseases. Earlier improved glycemic control 
is associated with reduced risk for cardiovascular disease in people with type 2 diabetes [1]. However, 
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more recent clinical trials have indicated that strict glycemic control does not necessarily prevent 
vascular complications [2]. Hence, beyond glycemic control, novel therapies to directly treat vascular 
disease are needed to improve the prognosis of people with type 2 diabetes. 
Angiogenesis is a physiological process involving the growth of new blood vessels from 
pre-existing vascular structures and the subsequent formation of vascular network. A number of 
abnormalities associated with angiogenesis have been observed in people with type 2 diabetes [3], and 
impaired angiogenesis is linked to the development of various vascular complications in diabetes 
mellitus. Compared with control subjects without diabetes, people with type 2 diabetes show poor 
development of coronary collateral vessels on coronary angiography [4]. Moreover, a previous study 
using autopsied hearts reported that people with diabetes have significantly lower capillary densities in 
areas of myocardial infarction [5]. These reports suggest that the angiogenic response to infarction 
and/or ischaemia is inhibited at the levels of capillaries and small arterioles in type 2 diabetes. 
Inadequate vascular formation could attenuate perfusion recovery in response to ischaemia, thereby 
partially accounting for the poor clinical outcomes in type 2 diabetic patients with coronary heart 
disease or peripheral artery disease [6, 7]. In addition, insufficient angiogenesis is involved in 
abnormal wound healing and the development of diabetic skin ulcers [8]. 
Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis under physiological 
and pathophysiological conditions. VEGF binds and phosphorylates its receptors, leading to the 
activation of a variety of signaling cascades such as MAPK and Akt. Angiogenic gene therapy using 
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plasmids encoding VEGF has been attempted in patients with coronary or peripheral artery diseases 
[9]. However, diabetes mellitus people often show a poor response to therapeutic angiogenesis [10]. 
Therefore, VEGF resistance, a defect of VEGF-related signal transduction, has been postulated as a 
molecular basis for the dysregulated angiogenesis in diabetes mellitus [3, 11]. The molecular 
mechanisms underlying VEGF resistance in diabetes mellitus are not fully understood. 
Selenoprotein P (SeP, encoded by the SEPP1 gene in human and the Sepp1 gene in mice) is a 
secretory protein produced primarily in the liver [12, 13]. It contains 10 selenocysteine residues and 
functions as a selenium supply protein [14]. We have previously reported that levels of serum SeP and 
hepatic gene expression of SEPP1 are elevated in type 2 diabetes [15]. More recently, Yang et al. have 
reported that serum levels of SeP are increased in people with impaired glucose tolerance [16]. SeP 
impairs insulin signal transduction and induced dysregulation of glucose metabolism in skeletal 
muscle and liver, indicating that SeP functions as a type 2 diabetes-associated hepatokine that causes 
insulin resistance and hyperglycemia [15]. SeP has heparin-binding properties [17] and is associated 
with endothelial cells in rat tissues [18], suggesting that SeP exerts some actions on vascular 
endothelial cells. A previous paper showed that SeP has an anti-oxidative action in vascular 
endothelial cells by using in vitro experiments [19]. Nevertheless, it is unknown whether SeP plays a 
role in the angiogenic response. 
We speculated that the liver-derived secretory protein SeP contributes to angiogenesis-associated 
vascular complications in type 2 diabetes by acting directly on vascular endothelial cells. In the current 
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study, we investigated the effects of SeP on angiogenesis in normal conditions, independently of diabetes, 
using purified SeP protein and Sepp1-deficient mice without the induction of diabetes. 
 
Methods 
Cell culture HUVECs were cultured in HuMedia EG2 (Kurabo, Osaka, Japan). H4-II-E-C3 cells were 
cultured in 10% FBS/DMEM (Gibco, Carlsbad, CA, USA) as previously described [20]. All cellular 
experiments were approved by the committee for cellular study at our institute. 
Animals Sepp1-deletion mice were produced by homologous recombination with genomic DNA 
cloned from a Sv-129 P1 library [21]. All animal studies were approved by the committee for animal 
study at our institute. See ESM for further details. 
Measurement of selenium Total selenium concentrations were determined by modification of 
Watkinson’s method [22, 23]. See ESM for further details. 
SEPP1 promoter assay The human SEPP1 promoter region was cloned to a luciferase reporter vector, 
and luciferase activities were measured using the Dual Luciferase assay system (Promega) [20]. See 
ESM for further details. 
Cell proliferation assay HUVECs were quantified using Cell Counting Kit-8 (Wako, Osaka, Japan). 
See ESM for further details. 
Migration assay HUVECs were seeded in the upper chamber of polycarbonate filters, and the migrated 
cell number across the filter was counted. See ESM for further details. 
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Cell tubule formation assay HUVECs were seeded on plates coated with ECMatrix gel. Endothelial 
tubule formation was photographed under microscope. See ESM for further details. 
Matrigel plug implantation assay This assay was performed using a Directed In Vivo Angiogenesis 
Assay Inhibition Kit (Trevigen Inc., Gaithersburg, MD, USA). See ESM for further details. 
Western blot analysis HUVECs were pretreated with SeP for 24 hours. After 2 hours of starvation, 
HUVECs were stimulated with VEGF for 15 min. See ESM for further details. 
RNA preparation and quantitative real-time Real-time PCR was performed on an ABI-Prism 7900HT 
(Applied Biosystems, Carlsbad, CA, USA). See ESM for further details. 
ROS generation Intracellular ROS levels were measured using 2’,7’-dichlorofluorescein diacetase 
(DCF) and quantified by Fluorescent plate reader (Fluoroskan Ascent FL, Yokohama, Japan). See 
ESM for further details. 
Purification of SeP SeP was purified from human plasma using conventional chromatographic 
methods [14, 24]. See ESM for further details. 
Preparation of human SEPP1 plasmid and overexpression of SeP in mice Human SEPP1 expression 
plasmid was given from KAKETSUKEN (The Chemo-Sero-Therapeutic Research Institute, Tokyo, 
Japan). The plasmid was injected into the tail vein of mice. See ESM for further details. 
Measurement of serum human SeP in mice injected with human SEPP1 plasmid Serum levels of 
human SeP were measured by enzyme-linked immunosorbent assays using two monoclonal antibodies 
[15, 25]. 
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Mouse wound healing model Full-thickness wound was created, and the extent of wound closure was 
examined. See ESM for further details. 
Hindlimb ischaemia model Mice underwent ligation and segmental resection of the left femoral vessel 
[26]. See ESM for further details. 
Identification of CD31+ vessels Antibody to CD31 was used for immunostaining. See ESM for further 
details. 
Calculations and statistical analysis All data were analyzed using SPSS version 11.0 (Japanese 
Windows Edition; SPSS, Inc.) See ESM for further details. 
 
Results 
Glucose increases gene expression and transcriptional activity for SeP in cultured hepatocytes To 
confirm the elevation of SeP in the liver of people and animal models with type 2 diabetes [15], we 
examined the action of glucose on the production of SeP in H4-II-EC hepatocytes (Fig. 1). Sepp1 
mRNA expression was significantly increased by 25 mmol/l of glucose in a time-dependent manner 
(Fig. 1a). Additionally, SEPP1 promoter activity as measured by luciferase activity was increased by 
25 mmol/l of glucose compared with mannitol (Fig. 1b). These results are consistent with our previous 
findings showing that treatment with high glucose increases protein levels of SeP in mouse primary 
hepatocytes [15]. These results indicate that high concentrations of glucose increase the transcriptional 
activity of SeP in the cultured hepatocytes. 
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SeP impairs VEGF-induced angiogenesis in endothelial cells To assess the direct action of the 
liver-derived secretory protein SeP on vascular endothelial cells, we treated HUVECs with purified 
human SeP protein. HUVECs were treated with 5 or 10 μg/ml of purified human SeP protein, the 
levels of which correspond to serum levels of SeP in healthy subjects or people with type 2 diabetes 
[15]. In addition, we confirmed that levels of selenium were undetectable (less than 2.5 ng/ml) in all 
the culture media used for HUVECs. VEGF-induced proliferation of HUVECs was significantly 
suppressed by treatment with 10 μg/ml of SeP (Fig. 2a). Co-administration of buthionone sulfoximine 
(BSO), an inhibitor of glutathione synthesis, partly rescued the suppressive effect of SeP. Next, we 
examined the effects of SeP on VEGF-induced migration in HUVECs. VEGF promoted the migration 
of HUVECs into a polycarbonate filters. This migration was inhibited by the addition of SeP in a 
concentration-dependent manner (Fig. 2b-c). In the absence of VEGF, treatment with SeP did not 
affect the migration of HUVECs, suggesting that SeP modulates VEGF-dependent migration of 
endothelial cells. We further examined the effects of SeP on tubule formation in HUVECs. HUVECs 
cultured on Matrigel containing VEGF showed morphological tubule formation, with a lumen 
surrounded by endothelial cells adhering to one another (Fig. 2d). SeP inhibited tubule formation of 
HUVECs in a concentration-dependent manner (Fig. 2d-e). These in vitro results indicate that SeP at 
physiological concentrations impairs VEGF-dependent angiogenesis of vascular endothelial cells. 
SeP reduces VEGF-stimulated formation of new vessels in Matrigel The role of SeP in angiogenesis in 
vivo was further determined by Matrigel plug implantation assay. Matrigel was mixed with VEGF in 
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the presence or absence of SeP protein and the plugs were implanted into the dorsal subcutaneous 
tissue of mice. Ten days later, angiogenesis inside Matrigel was quantified. SeP markedly inhibited 
VEGF-stimulated formation of new vessels in the Matrigel (Fig. 2f). These results further indicate that 
SeP impairs angiogenesis in vivo. 
SeP impairs VEGF signal transduction in endothelial cells Next, we determined whether SeP affects 
VEGF signal transduction in endothelial cells. Pretreatment with SeP impaired VEGF-stimulated 
phosphorylation of VEGFR2 (Tyr1175) and ERK1/2 (Thr202/Tyr204) in HUVECs (Fig.3a-b). 
Co-administration of BSO partially rescued the inhibitory effect of SeP on VEGF signaling (Fig. 3a-b). 
The receptor of VEGF, VEGFR2 (KDR), mRNA expression in HUVECs was unaffected by treatment 
with purified human SeP protein (Fig. 3c). These results indicate that SeP at physiological 
concentrations impairs VEGF signal transduction in vascular endothelial cells. 
SeP suppresses VEGF-induced acute generation of ROS in HUVECs To clarify the mechanism by 
which an anti-oxidative protein SeP impairs VEGF signaling, we assessed the action of SeP on the 
acute generation of reactive oxygen species (ROS) stimulated by VEGF. VEGF-induced ROS burst is 
reported to be required for the subsequent VEGF signal transduction [27]. Stimulation with 50 ng/ml 
of VEGF for 5 min significantly increased intracellular levels of ROS in HUVECs (Fig 3d). 
Pretreatment with SeP suppressed intracellular levels of ROS both with and without VEGF stimulation 
(Fig. 3d). These results suggest that SeP-induced VEGF resistance is associated with the reduction of 
ROS burst stimulated by VEGF. 
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SeP delays wound healing of skin in mice To clarify whether hepatic overexpression of SeP affects 
angiogenesis-related disorder in vivo, we used a hydrodynamic injection method to generate mice that 
overexpress human SEPP1 mRNA in the liver. Levels of SEPP1 gene expression in the liver and SeP 
protein in the blood were significantly elevated in these mice (Fig.4a-b), whereas serum levels of total 
selenium in wild-type and SeP-transgenic mice, which were 322.6 ng/ml and 331.0 ng/ml respectively, 
were not significantly different (Fig. 4c). We created excisional wounds (10 mm) in the dorsal skin of 
the mice and quantified the rate of wound healing. Wound closure was significantly impaired in the 
mice overexpressing SEPP1 at 3, 5 and 7 days (Fig. 4d-e). In contrast, Sepp1-/- mice showed an 
improvement of the wound closure at 9 days compared with the wild-type animals (Fig. 4f-g). These 
results indicate that the hepatokine SeP delays the wound healing of the skin in mice. 
Sepp1 heterozygous knockout mice show enhanced angiogenesis after hindlimb ischaemia To 
determine whether attenuation of SeP expression enhances angiogenesis in vivo, we generated 
hindlimb-ischaemia in Sepp1+/- mice. We previously reported that Sepp1-homozygous knockout mice 
exhibit enhancement of insulin signaling in skeletal muscle, whereas Sepp1-heterozygous knockout 
mice show marginal changes in insulin signaling [15]. Hence, we selected Sepp1-heterozygous 
knockout mice in the present study to assess the direct actions of SeP on the vascular system, 
independent of insulin signaling. 5 days after femoral artery ligation, Sepp1+/- mice showed a 
significant increase of blood flow compared with wild-type mice (Fig. 5a). This increase continued for 
15 days after artery ligation (Fig. 5b). Consistent with these findings, histological examination showed 
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increased vessel density in the hindlimb musculature as determined by immunostaining with 
anti-CD31 antibody (Fig. 5c-d). 
 
Discussion 
The present study indicates that the liver-derived secretory protein SeP impairs angiogenesis both in 
vitro and in vivo. SeP directly attenuates VEGF signal transduction in vascular endothelial cells, 
resulting in suppression of VEGF-induced cell proliferation, migration, and tube formation. We 
reported previously that levels of both hepatic SEPP1 mRNA and serum SeP protein are elevated in 
type 2 diabetes [15]. Taken together with our previous report, the present study suggests that hepatic 
overproduction of SeP may contribute to the onset of impaired angiogenesis in type 2 diabetes (Fig. 6). 
The attenuated VEGF signal transduction, VEGF resistance, has been postulated as the molecular 
mechanism underlying the dysregulation of angiogenesis in people with type 2 diabetes [3, 11]. 
Waltenberger et al. reported that circulating monocytes show attenuation of VEGF-induced 
chemotaxis in people with diabetes mellitus [28] and that VEGF-stimulated phosphorylation of 
downstream molecules is reduced in monocytes from patients with type 2 diabetes [29]. In addition, 
Sasso et al. found impaired VEGF signaling in the myocardium of type 2 diabetic patients with 
coronary heart disease [30], suggesting that diabetes induces VEGF resistance in not only monocytes 
but also other types of cells such as cardiomyocytes and endothelial cells. However, the molecular 
mechanisms by which VEGF resistance arises in diabetes mellitus have not been elucidated. The 
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results of the present study suggest a novel molecular pathology of type 2 diabetes; elevation of 
circulating SeP induces VEGF resistance in vascular endothelial cells. 
The liver is the production site of various secretory proteins. Recent work in our laboratory has 
indicated that genes encoding secretory proteins are abundantly expressed in the liver in type 2 
diabetes [31]. Moreover, genes encoding angiogenic factors, fibrogenic factors, and redox-associated 
factors are differentially expressed in the liver in type 2 diabetes, possibly contributing to the 
pathophysiology and clinical manifestations of this disease [32, 33]. The present study sheds light on a 
previously under-explored function of the liver; the liver may participate in the regulation of systemic 
angiogenesis by altering the production of angiogenesis-associated hepatokines such as SeP. 
Our observation that SeP impairs angiogenic processes is noteworthy in the context of experimental 
data suggesting that SeP plays a role in the anti-oxidative defense system [13]. In fact, we have shown 
previously that SeP increases the activity of glutathione peroxidase 1 (GPX1), a representative 
anti-oxidative enzyme that requires selenium for its enzymatic action, in Jurkat E6-1 cells, a human 
T-cell leukemia cell line [14]. SeP-induced activation of GPX1 was also demonstrated in endothelial 
cells [19]. Accumulating evidence indicates that reactive oxygen species (ROS) stimulate angiogenic 
response in order to initiate the tissue repair process in ischaemia-reperfusion lesions [34]. Among the 
growth factors involved in angiogenesis, VEGF plays a role in a ROS-dependent signal transduction 
system [27]. VEGF binding to VEGFR2 stimulates NADPH oxidase in endothelial cells, resulting in 
acute generation of ROS such as hydrogen peroxide. This ROS burst oxidizes and inactivates protein 
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tyrosine phosphatases, which negatively regulate VEGF signaling, and thereby promote VEGFR2 
phosphorylation and the subsequent signaling cascade [27]. 
In combination with these previous reports, the present data suggest that SeP induces VEGF 
resistance in endothelial cells by increasing GPX1 and subsequently suppressing the VEGF-induced 
ROS generation that is required for VEGF signal transduction. This speculation was supported by our 
findings that the co-administration of BSO, an inhibitor of glutathione synthesis, rescued the inhibitory 
effects of SeP on VEGF signaling and the subsequent VEGF responsiveness. The identification of SeP 
receptor(s) in endothelial cells would provide further insight into the molecular mechanism by which 
SeP impairs VEGF signal transduction. 
VEGF signaling is known to play paradoxical roles in the pathogenesis of diabetic complications. 
Both enhancement and suppression of angiogenesis are observed in different tissues in diabetic 
conditions [35]. In contrast to hindlimb ischaemia or wound healing, advanced diabetic retinopathy is 
characterized by VEGF-induced abnormal neovascularization in the retina. Current management for 
diabetic retinopathy includes anti-VEGF therapy along with blood glucose control [36]. In addition to 
retinopathy, growing evidence indicates that VEGF-related abnormal angiogenesis plays a major role 
in diabetic nephropathy [37]. Moreover, a recent report showed that pharmacological inhibition of 
VEGF-B improves glucose tolerance and insulin resistance in rodent models with type 2 diabetes 
[38]. Additional studies are needed to determine the actions of SeP on the enhanced angiogenesis in 
diabetic retinopathy or nephropathy. 
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Different from phosphorylation of VEGFR2 and ERK1/2, VEGF-induced phosphorylation of Akt, 
p38 MAPK, and AMPK was unchanged by SeP in HUVECs (data not shown). Although the detailed 
molecular mechanism by which SeP selectively impairs VEGFR2/ERK pathway in HUVECs is still 
unknown, SeP might act on ERK-selective MAPK phosphatases [39]. In fact, some kinds of MAPK 
phosphatases are inactivated by intracellular oxidative stress [39]. However, SeP-induced selective 
impairment of VEGFR2/ERK pathway should be confirmed in the other vascular endothelial cells 
except HUVECs. 
All the culture media we used for HUVECs in this study contain 5.5 mM of glucose, which 
corresponds to fasting plasma glucose levels in people with normal glucose tolerance. However, we 
confirmed that SeP also attenuated VEGF signaling of HUVECs in the presence of 25 mM of glucose 
(data not shown). These results suggest that SeP induces VEGF resistance in HUVECs on both 
normoglycemic and hyperglycemic conditions. However, additional experiments are clearly needed to 
determine whether SeP sufficiently remove hyperglycemia-induced chronic oxidative stress in 
vascular endothelial cells. 
We have shown that serum levels of total selenium were unchanged in the mice injected with SEPP1 
plasmid compared with the control animals (Fig. 4c), in spite of the significant elevation of serum SeP 
(Fig. 4b). Selenium content in the other forms except SeP might decrease in the serum of the SeP 
transgenic mice compensatively [14, 40]. Because a recent report showed that SeP exerts 
anti-oxidative actions independently of selenium supply [41], we speculate that the phenotype of the 
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SeP transgenic mice reflects the action of SeP itself, but not the abnormal selenium distribution in 
mice. 
Sepp1-heterozygous knockout mice exhibit an increase of angiogenesis during hindlimb ischaemia 
without the induction of diabetes (Figure 5), suggesting that the hepatokine SeP plays a role in the 
regulation of systemic angiogenesis, irrespective of diabetes status. For example, 
lipopolysacchadire-induced acute inflammation was reported to down-regulate the production of SeP 
in mice [42]. Angiogenesis promoted by suppressed production of SeP might be beneficial in 
inflammatory conditions. Further characterization of Sepp1-deficient mice will provide insights into 
the involvement of SeP in the regulation of angiogenesis in normoglycemic condition. 
Serum levels of human SeP in the mice injected with human SEPP1 plasmid reached approximately 
2.0 μg/ml (Fig. 4b). These levels correspond to the incremental changes of serum levels of SeP in 
people with normal glucose tolerance to those with type 2 diabetes in Japanese population [15, 25]. 
This strongly suggests that the phenotype observed in the SeP transgenic mice reflects the 
physiological actions of SeP. 
One limitation of the present study is that we examined the action of SeP on endothelial cells only. 
Various types of cells participate in the angiogenic processes. Further studies are necessary to 
determine whether SeP exerts effects on other cell types such as the monocytes or endothelial 
progenitor cells. 
Another limitation of the present study is that we carried out all the experiments of Sepp1-deficient 
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mice without the induction of diabetes by use of high fat diet or streptozotocin. Hence, we did not 
investigate the contribution of SeP in the development of the dysregulated angiogenesis seen in 
diabetes in vivo. However, our data indicate that treatment with purified SeP directly inhibits 
angiogenesis in both vascular endothelial cells and mice on euglycemic conditions. Combined with the 
previous reports showing the elevated production of SeP in type 2 diabetes [15, 16], the current data 
suggest that overproduction of SeP contributes to the onset of impaired angiogenesis in type 2 diabetes. 
However, further studies in animals with diabetes are necessary to determine the degree of the 
contribution of SeP on the impaired angiogenesis observed in diabetes. 
In summary, the present study indicates that the diabetes-associated hepatokine SeP impairs 
angiogenesis by reducing VEGF signal transduction in endothelial cells, and suggests that SeP may be a 
novel therapeutic target for treatment of VEGF resistance in people with type 2 diabetes. 
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Legends for figures 
 
Fig. 1 Glucose increases gene expression and transcriptional activity for SeP in H4-II-EC3 hepatocytes. 
(a) Relative Sepp1 mRNA expression normalized to b-Act, (b) Promoter activity for SEPP1 in 
H4-II-EC3 hepatocytes treated with glucose (white) and mannitol (black). Data are mean ±SD, n = 3, 
***p < 0.001 
 
Fig. 2 SeP suppresses VEGF-stimulated angiogenesis in vascular endothelial cells. (a) Cell 
proliferation in HUVECs treated with VEGF for 48 hours (n = 12). (b) Representative images of 
HUVECs that migrated across the polycarbonate filters (magnification, x200). (c) Quantification of 
HUVECs that migrated across the filters (n = 8). (d) Representative images of HUVECs that were 
subjected to Matrigel tubule formation assay (magnification, x400). (e) Quantification of total tubule 
length of HUVECs (n = 9). (f) Matrigel implant assay in mice (n = 6-8). Black bar: Control; dark-grey 
bar: SeP 5 μg/ml; white bar: SeP 10 μg/ml; light-grey bar: SeP 10 μg/ml and BSO 0.2 mmol/l in (a), (c), 
(e) and (f). Data are mean ± SEM in (a), (c), (d), and (f). *p < 0.05. **p < 0.01. 
 
Fig. 3 SeP impairs VEGF signal transduction in endothelial cells. (a) VEGF signaling in HUVECs 
treated with SeP (10 μg/ml). (b) Quantification of phosphorylated VEGFR2 and ERK in HUVECs (n = 
6). (c) Gene expression levels for VEGFR2 (KDR) in HUVECs treated with SeP for 24 hours 
normalized to GAPDH (n = 6). (d) ROS levels in HUVECs that were stimulated with VEGF for 5 min. 
(n = 8). ROS levels were measured as DCF fluorescence intensity. Black bar: Control; dark-grey bar: 
SeP 5 μg/ml; white bar: SeP 10 μg/ml; light-grey bar: SeP 10 μg/ml and BSO 0.2 mmol/l in (b)-(d). 
Data are mean ± SEM in (b)-(d). *p < 0.05, **p < 0.01. 
 
Fig. 4 Hepatic overexpression of SeP impairs wound healing in mice. (a) Levels of human SEPP1 
mRNA normalized to 18s rRNA in the livers of mice injected with plasmid DNA via the tail vein (n 
= 9). (b) Serum human SeP levels in mice injected with a plasmid encoding SEPP1 (n = 9). (c) Serum 
levels of selenium in mice injected with a plasmid encoding SEPP1 (n = 3). (d) Representative images 
of full-thickness excision rounds on the backs of mice injected with SEPP1 plasmid. (e) Quantification 
of wound closure in mice injected with SEPP1 plasmid (white circle) and control (black circle) (n = 9). 
(f) Representative images of full-thickness excisional wounds on the backs of Sepp1-/- mice. (g) 
Quantification of wound closure in Sepp1-/- mice (white circle) and control (black circle) (n = 6-12). 
Data are mean ± SEM in (a), (b), (c), (e), and (g). *p < 0.05, Scale bars: 10 mm in (d) and (f). 
 
Fig. 5 Sepp1+/- mice show enhanced angiogenesis during hindlimb ischaemia. (a) Representative 
images of perfusion recovery following hindlimb ischaemia in Sepp1+/- mice. (b) Quantification of 
blood flow recovery in Sepp1+/- mice (white circle) and control (black circle) (n = 5). The ratio of 
24 
relative blood flow was calculated by dividing the laser Doppler-derived perfusion of the ischaemic 
hindlimb by non-ischaemic. (c) Representative images of CD31 stained sections of lower limb tissues 
of Sepp1+/- mice in 15 days after ligation. Scale bars: 100 μm (d) Quantification of CD31-positive cells 
in the hindlimb of Sepp1+/- mice (white bar) and WT (black bar). Data are from 16 fields per section. 
Data are mean ± SEM in (b), and (d). *p < 0.05, **p < 0.01. 
 
Fig. 6 Overproduction of SeP in Type 2 diabetic liver induces VEGF resistance in vascular endothelial 
cells. (a) SeP inhibits VEGF signal transduction by suppressing acute generation of ROS, resulting in 
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Materials The materials used and their sources were as follows: VEGF (Pepro Tech, London, UK), 
HuMedia EG2 (Kurabo, Osaka, Japan), EBM-2 (Takara Bio, Otsu, Japan) and M199 medium (Gibco, 
Carlsbad, CA, USA), DMEM (Gibco), Matrigel (Chemicon, Billerica, MA, USA), BSO, Bovine serum 
albumin (BSA) and fatty acid free BSA (Sigma-Aldrich, St Louis, MO, USA), FBS (JRH Biosciences, 
St Louis, MO, USA), antibodies against phospho-VEGFR2 (Tyr1175), VEGFR2, phospho-ERK1/2 
(Thr202/Tyr204), ERK1/2, phospho-Akt (Ser473), Akt, phospho-p38MAPK, p38MAPK antibody 
(Cell Signaling Technology, Boston, MA, USA), and CD31 antibody (BD, San Jose, CA, USA). 
Unless otherwise indicated, all other chemicals were purchased from Sigma-Aldrich. 
 
Animals Male C57BL/6J mice, 6weeks of age, were purchased from Charles River Laboratories Japan 
(Yokohama, Japan). Sepp1-deletion mice were produced by homologous recombination with genomic 
DNA cloned from a Sv-129 P1 library, as described previously [1]. All animal studies were reviewed 
and approved by the committee for animal study at our institute, and were conducted in accordance 
with established standards for human handling. 
 
Measurement of selenium Total selenium concentrations in mouse serum and culture medium were 
determined by modification of Watkinson’s method [2,3]. The method was based on the measurement 
of the fluorescence of piazselenol resulted from reaction of selenite with 2,3-diaminonaphtalene 
(DAN). The pretreated samples were measured fluorometrically (emission at 525 nm upon excitation 
at 378 nm) with a HITACH F2700 fluorescence spectrophotometer (HITACHI High-Technologies, 
Tokyo, Japan). The accuracy of the selenium analysis was checked by measurement of the reference 
material, Seronorm Trace Elements Serum L-2, REF 203105, LOT 0903107 (SERO, Billingstad, 
Norway). The average of obtained results (163.75 μg/ml) of the reference material serum fell within 
the recommended range (153-173 μg/ml) by SERO. 
 
SEPP1 promoter assay The human SEPP1 promoter region was cloned to a luciferase reporter vector 
as were ported previously [4]. H4-II-EC3 hepatocytes were grown to 40-50% in 24-well plates and 
transfected with 0.4 μg of plasmid DNA encoding a luciferase reporter vector per well together with 
1.2-μl FuGENE6 (Promega, Madiosn, WI, USA). 24 hours later, the cells were washed with 
phosphate-buffered saline and starved in glucose free DMEM (Gibco) for 3 hours. Then, the cells were 
treated with 25 mmol/l of glucose or mannitol diluted with glucose free DMEM for the indicated times. 
Luciferase activities were measured using the Dual Luciferase assay system (Promega, Madison, WI, 
USA), as we described previously [4]. 
 
Cell proliferation assay HUVECs were seeded on 96-well plates (BD) at a density of 2×103 cells/well 
in 100 μl. After 3 hours of starvation in growth factor-free HuMedia at 37°C, HUVECs were incubated 
in HuMedia with VEGF (20 ng/ml) and SeP for 48 hours. Cell numbers were quantified by measuring 
optical density at 450 nm using Cell Counting Kit-8 (Wako, Osaka, Japan). 
 
Migration assay Cell Migration was assessed using polycarbonate filters with a pore size of 8 μm 
(Neuro Probe, Inc., Gaithersburg, MD, USA). HUVECs were pretreated with SeP in M199 containing 
1% FBS for 24 hours. The HUVECs were then starved in EBM-2 containing 0.5% BSA for 3 hours. 
The indicated concentrations of VEGF and SeP in EBM-2 containing 0.25% fatty acid free BSA were 
placed in the lower chamber of the filter. HUVECs (1×104) in 36 μl of EBM-2 containing 0.25% fatty 
acid-free BSA were seeded in the upper chamber. The apparatus was incubated for 15 hours. The 
migrated cell number across the filter was counted in 16 high-power (×200) fields per insert. 
 
Cell tubule formation assay 96-well plates were coated with ECMatrix gel, and the Matrigel was 
allowed to solidify for 60 min at 37°C. HUVECs (1×104) in 100 μl of M199 medium containing 5% 
FBS with various concentrations of SeP were seeded onto each well. After incubation at 37°C for 11 
hours, endothelial tubule formation was photographed under microscope. Tubule length was measured 
with Image J software to quantify the length of tubular structures. 
 
Matrigel plug implantation assay 20 μl plug of Matrigel containing VEGF (40 ng/ml) with SeP were 
planted into the subcutaneous tissue on the back of WT mice. On day 10 after implantation, the 
Matrigel plug was removed and gel was collected by centrifugation. The collected cells were labeled 
with FITC-lectin. Angiogenesis was quantified by measuring fluorescence intensity in 96-well plates 
(excitation, 485 nm; emission, 510 nm). 
 
Western blot analysis HUVECs were pretreated with SeP for 24 hours. After 2 hours of starvation with 
serum-free M199 medium, HUVECs were stimulated with VEGF (20 ng/ml) for 15 min. Cells were 
lysed immediately with modified RIPA buffer. Lysates (containing 6-15 μg of protein) were 
immunoblotted with antibodies to phospho-VEGFR2 (Tyr1175), phospho-ERK1/2 (Thr202/Tyr204), 
ERK1/2, or actin. Immunoreactive bands were detected using ECL Prime and were visualized using 
LAS-3000 (FUJIFILM, Tokyo, Japan). 
 
RNA preparation and quantitative real-time PCR Total RNA was isolated from frozen liver with a 
QuickGene RNA Tissue Kit SII (FUJIFILM). Total RNA (100 ng) was used to synthesize cDNA with 
a High-Capacity cDNA Archive kit (Applied Biosystems, Carlsbad, CA, USA). Real-time PCR was 
performed on an ABI-Prism 7900HT (Applied Biosystems). The specific PCR primers and TaqMan 
probe were obtained from Applied Biosystems. The PCR conditions were one cycle of 50℃ for 2 min 
and 95℃ for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. 
 
ROS generation Intracellular HUVECs were pretreated with SeP for 24 hours in HuMedia EG2. After 
2 hours of starvation with serum-free M199 medium and 30 min of treatment with DCF, HUVECs 
were stimulated with VEGF (50 ng/ml) for 5 min. ROS generation was quantified by Fluorescent plate 
reader (Fluoroskan Ascent FL, Yokohama, Japan). 
 
Purification of SeP SeP was purified from human plasma using conventional chromatographic 
methods, as previously described [5,6]. Homogeneity of purified human SeP was confirmed by 
analysis of both amino acid composition and sequence [6]. Concentrations of purified SeP were 
measured by the Bradford method, using bovine immunoglobulin G as a standard. 
 
Preparation of human SEPP1 plasmid and overexpression of SeP in mice The human SEPP1 gene was 
cloned into the pBR322 expression vector, and control plasmid DNA was also produced. 55 μg of 
human SEPP1 pDNA or control pDNA in 1.8 ml of phosphate-buffered saline (pH 7.4, CaCl2-, 
MgCl2-) were injected within 10 s into the tail vein of male C57BL/6J mice weighing 25 g each using 
a 26G needle. Two days after injection, SEPP1 mRNA expression in the liver of mice was quantified 
by real-time PCR. 
 
Mouse wound healing model A circle of 10 mm in diameter was drawn on the skin of the mid-dorsal 
region, and a full-thickness wound was created by excision of the area with scissors. The extent of 
wound closure was examined after wounding. 
 
Hindlimb ischaemia model Mice underwent ligation and segmental resection of the left femoral vessel 
as described previously [7]. The blood flow was measured with a laser-Doppler perfusion scanner. The 
ratio of the relative blood flow was calculated by dividing the perfusion of the ischaemic hindlimb by 
that of the non-ischaemic. 
 
Identification of CD31+ vessels 5-μm sections of muscle were acetonized and incubated with primary 
antibody to CD31 (PECAM-1, BD557355; 1:100) (BD) overnight at 4°C. The sections were then 
incubated with a rat-specific antibody. Immunohistochemical signals were developed with 3, 3’- 
diaminobenzidine substrate. 
 
Calculations and statistical analysis Numeric values are reported as mean ± SEM. Differences 
between two groups were assessed with the unpaired two-tailed t-tests. Data involving more than two 
groups were assessed by analysis of variance (ANOVA) with Bonferroni adjustment for multiple 
comparisons. In all analyses, P<0.05 was taken to indicate statistical significance. 
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